News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
By 2034, the Pneumatic Nebulizers Market is projected to grow at a compound annual growth rate of 6.5% to reach USD 1,501.83 million | PMR - ForexTV
The market for pneumatic nebulizers has been expanding significantly as a result of the growing need for efficient home healthcare solutions and asthma devices.New York, USA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Market Overview In 2024, the pneumatic nebulizers market is estimated to be worth USD 803.87 million. The market is expected to expand at a compound annual growth rate of 6.5% from 2025 to 2034, from USD 854.61 million in 2025 to USD 1,501.83 million by 2034. Market Introduction Pneumatic nebulizers are machines that turn liquid drugs into an aerosol or mist that can be inhaled through a mask or mouthpiece. Chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma are among the respiratory disorders they are used to treat. Using oxygen or compressed air, pneumatic nebulizers produce a high-velocity stream of air that disperses the liquid medication into tiny droplets. Under a doctor's supervision, pneumatic nebulizers can be used at home in addition to in medical settings. All kinds of medications can be administered with pneumatic nebulizers, which are also less costly than other nebulizer types and simple to use. Pneumatic nebulizers can also be used in industrial and laboratory settings to nebulize liquids and solutions. Download Free Sample PDF Copy of Report: https://www.polarismarketresearch.com/industry-analysis/pneumatic-nebulizers-market/request-for-sample?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Pneumatic Nebulizers Market Details Report Attributes DetailsMarket value in 2024USD 803.87Market value in 2034USD 1,501.83 millionCAGR6.5 %Base year2024Historical data2020 – 2023Forecast period2024 – 2034 Key Takeaways from Report Global leaders and up-and-coming regional competitors fighting for market share are influencing the competitive environment of the pneumatic nebulizers industry. Prominent businesses concentrate on developing new products, using their strong R&D capacities and wide distribution networks to provide cutting-edge pneumatic nebulizers market solutions for a range of uses in clinics, hospitals, and home healthcare.The pneumatic nebulizers market is fundamentally segmented based on the induction, end-use, and regional outlook.Because of its sophisticated healthcare system, high prevalence of respiratory conditions like asthma and COPD, and robust uptake of cutting-edge medical technology, North America dominated the pneumatic nebulizers market in 2024. Request for a Discount on this Report Before Purchase: https://www.polarismarketresearch.com/industry-analysis/pneumatic-nebulizers-market/request-for-discount-pricing?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Growth Drivers Increased Chronic Respiratory Disease Prevalence Nebulizers are an efficient method of delivering medication directly to the lungs, providing immediate relief from chronic respiratory conditions like asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), which frequently require long-term treatment. Pneumatic nebulizer demand is predicted to rise as respiratory illnesses continue to rise globally, particularly as a result of smoking and pollution, spurring innovation and pneumatic nebulizers market expansion. Developments in Pneumatic Nebulizer Technology Technological developments in pneumatic nebulizers are transforming how respiratory treatments are administered. Innovations like smaller and quieter designs greatly improve patient convenience and comfort. Furthermore, by only releasing medication during inhalation, breath-actuated nebulizers increase efficiency and reduce waste. Real-time monitoring and data collection are made possible by the development of smart nebulizers with digital interfaces, which allows for more individualized treatment regimens. The increased effectiveness, accessibility, and ease of use of pneumatic nebulizers due to these technological advancements is encouraging their use in both clinical and home care settings thus propelling the pneumatic nebulizers market growth. Regional Analysis North America dominated the pneumatic nebulizers market in 2024 because of its highly developed healthcare system, high prevalence of respiratory conditions like COPD and asthma, and robust uptake of cutting-edge medical technology. Additionally, the regional market benefits from a high demand for at-home and in-hospital care, as patients use nebulizers more frequently to manage chronic conditions. Key players in the market drive market leadership in the area by supporting the widespread use of these devices and providing strong healthcare funding. In the upcoming years, the Asia Pacific market for pneumatic nebulizers is anticipated to grow at a substantial compound annual growth rate (CAGR) because of factors like growing air pollution, easier access to healthcare, and increased awareness of respiratory illnesses. Nebulizer adoption in hospitals and homecare settings is also being aided by growing healthcare infrastructure, especially in developing nations. Inquire more about this report before purchase: https://www.polarismarketresearch.com/industry-analysis/pneumatic-nebulizers-market/inquire-before-buying?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Pneumatic Nebulizers Market Segmentation OverviewBy Indication Outlook (Revenue, USD Million, 2025–2034) Breath-AcuratedVented By End Use Outlook (Revenue, USD Million, 2025–2034) Hospitals & ClinicsHome Healthcare By Regional Outlook (Revenue, USD Million, 2025–2034) North America USCanada Europe GermanyFranceUKItalySpainNetherlandsRussiaRest of Europe Asia Pacific ChinaJapanIndiaMalaysiaSouth KoreaIndonesiaAustraliaVietnamRest of Asia Pacific Middle East & Africa Saudi ArabiaUAEIsraelSouth AfricaRest of Middle East & Africa Latin America MexicoBrazilArgentinaRest of Latin America Digestive & Intestinal Remedies Market: https://www.polarismarketresearch.com/industry-analysis/digestive-and-intestinal-remedies-market Non-alcoholic Steatohepatitis Treatment Market: https://www.polarismarketresearch.com/industry-analysis/non-alcoholic-steatohepatitis-treatment-market Paracetamol IV Market: https://www.polarismarketresearch.com/industry-analysis/paracetamol-iv-market Personalized Medicine Biomarkers Market: https://www.polarismarketresearch.com/industry-analysis/personalized-medicine-biomarkers-market Medical Device Engineering Market: https://www.polarismarketresearch.com/industry-analysis/medical-device-engineering-market Patient Support Technology Market: https://www.polarismarketresearch.com/industry-analysis/patient-support-technology-market About Polaris Market Research & Consulting, Inc: Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers. Contact: Likhil G 8 The Green Ste 19824, Dover, DE 19901, United States Phone: +1-929 297-9727 Email: sales@polarismarketresearch.com Web: https://www.polarismarketresearch.com Follow Us: LinkedIn | Twitter
Borage Oil Market is expected to reach USD 104.34 million by 2034, representing a CAGR of 5.9%. | PMR - ForexTV
The shift toward natural ingredients is increasing the popularity of borage oil among manufacturers and consumers, contributing to the borage oil market's growth.New York, USA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Market Overview The borage oil market is expected to be worth USD 55.34 million by 2024. The market is expected to grow from USD 58.95 million in 2025 to USD 104.34 million by 2034, representing a CAGR of 5.9 % from 2024 to 2034. Market Introduction Borage oil is an herbal oil derived from the seeds of the borage plant, also known as starflower. Borage oil contains high levels of gamma-linolenic acid (GLA), as well as other fatty acids, vitamins, and minerals. Borage oil is used to treat skin conditions, inflammatory disorders, and cardiovascular and endocrine problems. It is also used as a dietary supplement to treat joint inflammation and rheumatoid arthritis. Borage oil's anti-inflammatory properties stem from its high GLA content. GLA is converted into prostaglandins, which help regulate the immune system and fight inflammation. Borage oil is not recommended for pregnant women or those who have liver problems. Download Free Sample PDF Copy of Report: https://www.polarismarketresearch.com/industry-analysis/borage-oil-market/request-for-sample?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Report Features Market Data: A thorough examination of market projections and annual sales in USD millions from 2025 to 2034. Regional Analysis: Comprehensive analyses of all major market regions, including the Middle East and Africa, Asia Pacific, Latin America, Europe, and North America. Company Profiles: Coverage of significant businesses in the borage oil market, such as A.G. Organica Pvt. Ltd., AOS Products Pvt. Ltd., ConnOils by Kraft, Icelandirect, LLC, K.K. ENTERPRISE, and Parchem. Customization: Get reports tailored to your specific requirements in terms of countries, regions, and segmentation. Important Players in Borage Oil Market A.G. Organica Pvt. Ltd., AOS Products Pvt. Ltd., ConnOils by Kraft, Icelandirect, LLC, K.K. ENTERPRISE, Parchem, William Hodgson and Co, Avestia Pharma, Nordic Naturals, Kerfoot Group, Soyatech International, USANA Health Sciences Inc., and O&3 are among the key players in the borage oil market. These companies use strategic initiatives like mergers, acquisitions, partnerships, and collaborations to improve their product offerings and enter new markets. Request for a Discount on this Report Before Purchase: https://www.polarismarketresearch.com/industry-analysis/borage-oil-market/request-for-discount-pricing?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Borage Oil Market Growth Drivers Expansion of Skincare Industry With consumers seeking more effective and natural skincare ingredients, borage oil is gaining popularity for its hydrating and soothing properties. Borage oil is being used in cosmetic formulations due to its ability to improve skin elasticity and reduce inflammation. With the continued growth of the skincare industry, the demand for borage oil among manufacturers is expected to increase, propelling the borage oil market forward. Growth of E-Commerce Sector The market for borage oil is increasingly being driven by the expanding e-commerce industry. Customers now have easier access to natural health products like borage oil, which is becoming more and more well-liked for its anti-inflammatory and skin-benefitting qualities, thanks to the growth of online shopping. Customers can easily and conveniently buy borage oil in a variety of forms, including oils, creams, and capsules, through e-commerce platforms. Because more people are shopping for health and wellness products online, this accessibility is increasing borage oil market demand. Borage Oil Market Regional Analysis North America Because of a rise in personal spending, North America had the biggest revenue share in the borage oil market in 2024. The demand for natural ingredients like borage oil is rising as a result of people spending more on their health and beauty needs. Therefore, the demand for borage oil is being driven by the increase in spending in North America. Asia Pacific Asia Pacific borage oil market is expected to grow significantly during the forecast period due to the expansion of the food and beverage industry. As more consumers seek natural and healthy ingredients in their diets, borage oil is gaining popularity for its nutritional benefits and potential health benefits. The growing demand for natural food products is driving manufacturers to incorporate borage oil into a variety of food and beverage applications, boosting market growth in Asia Pacific. Inquire more about this report before purchase: https://www.polarismarketresearch.com/industry-analysis/borage-oil-market/inquire-before-buying?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Borage Oil Market Segmentation By Nature Outlook (USD Million, 2020–2034) OrganicConventional By Delivery Form Outlook (USD Million, 2020–2034) LiquidCapsule By Application Outlook (USD Million, 2020–2034) Skin CareAnti-InflammatoryAntioxidantHaircareAnti-Ageing By Distribution Channel Outlook (USD Million, 2020–2034) OnlineRetailPharmacies By End Use Outlook (USD Million, 2020–2034) PharmaceuticalCosmeticsFood and BeveragesAnimal Feed By Regional Outlook (USD Million, 2020–2034) North America USCanada Europe GermanyFranceUKItalySpainNetherlandsRussiaRest of Europe Asia Pacific ChinaJapanIndiaMalaysiaSouth KoreaIndonesiaAustraliaRest of Asia Pacific Middle East & Africa Saudi ArabiaUAEIsraelSouth AfricaRest of Middle East & Africa Latin America MexicoBrazilArgentinaRest of Latin America Browse Related Reports: CPP Films Market: https://www.polarismarketresearch.com/industry-analysis/cast-polypropylene-films-market Popcorn Container Market: https://www.polarismarketresearch.com/industry-analysis/popcorn-container-market Board Insulation Market: https://www.polarismarketresearch.com/industry-analysis/board-insulation-market Blasting Automation Services Market: https://www.polarismarketresearch.com/industry-analysis/blasting-automation-services-market Building and Construction Sheets Market: https://www.polarismarketresearch.com/industry-analysis/building-and-construction-sheets-market Elastomer Gel in Personal Care Market: https://www.polarismarketresearch.com/industry-analysis/elastomer-gel-in-personal-care-market s About Polaris Market Research & Consulting, Inc: Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers. Contact: Likhil G 8 The Green Ste 19824, Dover, DE 19901, United States Phone: +1-929 297-9727 Email: sales@polarismarketresearch.com Web: https://www.polarismarketresearch.com Follow Us: LinkedIn | Twitter
mRNA Vaccines and Therapeutics Market Expected to Reach USD 253.83 Billion By 2034, With 16.7% CAGR From 2025 to 2034 | PMR - ForexTV
The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide.New York, USA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Market Overview The market for mRNA vaccines and therapeutics is poised to grow, according to the latest research study by Polaris Market Research. The mRNA vaccines and therapeutics market size was valued at USD 54.32 billion in 2024 and is projected to grow to USD 253.83 billion by 2034. It is anticipated to register a CAGR of 16.7% during 2025–2034. Market Introduction Messenger ribonucleic acid (mRNA) is a type of single-stranded RNA that acts as a basis for protein synthesis in the cells. mRNA and therapeutics combine the desirable immunological properties and work by introducing a mRNA strand corresponding to a single protein. Cells then use the mRNA to produce the viral protein. After this, the immune system responds to it by developing specific proteins called antibodies. Antibodies help the body fight infection by recognizing and binding to antigens, which are sugars or proteins found on the surface of pathogens or toxins. Once produced, the antibodies stay in the body even after the pathogen or virus has been destroyed. Download Free Sample PDF Copy of Report: https://www.polarismarketresearch.com/industry-analysis/mrna-vaccines-and-therapeutics-market/request-for-sample?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Market Report Scope Report AttributesDetailsMarket Size Value in 2024USD 54.32 billionMarket Size Value in 2025USD 63.28 billionRevenue Forecast by 2034USD 253.83 billionCAGR16.7% from 2025 to 2034Base Year2024Historical Data2020–2023Forecast Period2025–2034 Market Key Players The leading market participants are focusing on R&D to expand their product offerings. Also, they are adopting several strategic initiatives to expand their global presence. A few of the mRNA vaccines and therapeutics market key players are: Pfizer Inc.Moderna, Inc.BioNTech SEGlaxoSmithKlineCureVac N.V.AstraZenecaKernal BiologicsPantherna TherapeuticspHion TherapeuticsRecode TherapeuticsStrand Therapeutics Market Drivers and Opportunities Rising R&D Initiatives and Strategic Partnerships: The leading market participants and key companies are increasingly focusing on R&D and strategic partnerships to accelerate the development of new mRNA vaccines. They are pooling expertise, technologies, and talent to overcome manufacturing and scientific challenges. Thus, the growing focus on R&D and the adoption of strategic partnerships is fueling the mRNA vaccines and therapeutics market development. Increased Regulatory Approvals: Regulatory approvals play a crucial role in building public confidence and encouraging broader applications of mRNA vaccines in healthcare. In addition, they pave the way for additional investments in mRNA vaccines and therapeutics, research, development, and production infrastructure, facilitating mass manufacturing of innovative products. Growing Incidence of Infectious Diseases: The rising prevalence of infectious diseases worldwide has prompted market participants to develop vaccines that can adapt to various virus variants. This, in turn, has fueled the mRNA vaccines and therapeutics market demand across the globe. Request For Discount on This Report Before Purchase: https://www.polarismarketresearch.com/industry-analysis/mrna-vaccines-and-therapeutics-market/request-for-discount-pricing?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Regional Overview The research report offers market insights into all the key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America: North America dominated the mRNA vaccines and therapeutics market in 2024. The regional market dominance is primarily fueled by the presence of a robust healthcare infrastructure and significant investments in research and development. In addition, high awareness of medical technologies and a strong regulatory framework further contribute to the robust growth of the market in the region. Asia Pacific: The Asia Pacific mRNA vaccines and therapeutics market is projected to register the fastest CAGR from 2025 to 2034. The increasing investments in biotechnology and the growing prevalence of infectious diseases are driving the demand for mRNA vaccines and therapeutics in Asia Pacific. Strategic partnerships and collaborations have further accelerated the innovation and production of mRNA vaccines in the region. Inquire More About This Report Before Purchase: https://www.polarismarketresearch.com/industry-analysis/mrna-vaccines-and-therapeutics-market/inquire-before-buying?utm_source=gnw&utm_medium=gnw&utm_campaign=globe&utm_id=01 Market Segmentation By Type Outlook Self-Amplifying mRNA-based VaccinesConventional Non-Amplifying mRNA-Based Vaccines By Application Outlook CancerInfectious DiseasesAutoimmune DiseasesOthers By Treatment Type Outlook Monoclonal AntibodyGene TherapyCell TherapyOther By End User Outlook Research Laboratories and OrganizationsHospitalsClinicsOthers By Regional Outlook North America USCanada Europe GermanyFranceUKItalySpainNetherlandsRussiaRest of Europe Asia Pacific ChinaJapanIndiaMalaysiaSouth KoreaIndonesiaAustraliaVietnamRest of Asia Pacific Middle East & Africa Saudi ArabiaUAEIsraelSouth AfricaRest of Middle East & Africa Latin America MexicoBrazilArgentinaRest of Latin America Browse Related Reports: Blood Pressure Cuffs Market: https://www.polarismarketresearch.com/industry-analysis/blood-pressure-cuffs-market Hematology Analyzers and Reagents Market: https://www.polarismarketresearch.com/industry-analysis/hematology-analyzers-and-reagents-market Surgical Sponges Market: https://www.polarismarketresearch.com/industry-analysis/surgical-sponges-market Liposomal Doxorubicin Market: https://www.polarismarketresearch.com/industry-analysis/liposomal-doxorubicin-market Angina Pectoris Drugs Market: https://www.polarismarketresearch.com/industry-analysis/angina-pectoris-drugs-market Arthroscopy Market: https://www.polarismarketresearch.com/industry-analysis/arthroscopy-market About Polaris Market Research & Consulting, Inc: Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers. Contact: Likhil G 8 The Green Ste 19824, Dover, DE 19901, United States Phone: +1-929 297-9727 Email: sales@polarismarketresearch.com Web: https://www.polarismarketresearch.com Follow Us: LinkedIn | Twitter
Singapore Industrial Production Growth Accelerates - ForexTV
Singapore experienced a rebound in industrial production growth, following a significant slowdown in the two preceding months, according to preliminary figures released by the Economic Development Board on Thursday.In November, industrial production increased by 8.5% year-on-year, an improvement from the 1.2% rise observed in October, which marked the slowest growth since the upward trend began in July. This figure, however, fell short of the anticipated 10.0% growth rate.When excluding the biomedical manufacturing sector, industrial production surged by 13.0% in November, a substantial rise from the mere 0.4% seen in the previous month.On a month-to-month comparison, industrial production saw a marginal decrease of 0.4% in November, following a slight uptick of 0.1% in October.Breaking it down by sectors, the electronics cluster witnessed a remarkable 26.2% annual increase in output in November, while precision engineering recorded a modest rise of 0.6%, largely driven by heightened production of front-end semiconductor equipment.Conversely, the biomedical manufacturing sector experienced a significant downturn, with output plummeting by 21.2% from the previous year. Meanwhile, the general manufacturing output also fell, registering a 2.6% decline.The material has been provided by InstaForex Company - www.instaforex.com
European Markets Closed For Boxing Day Holiday - ForexTV
Stock markets worldwide are predominantly closed today due to the festive season. In Europe, key financial hubs such as Germany, France, London, Spain, and Switzerland are observing the Boxing Day holiday, resulting in a pause in trading activities.In the Asia-Pacific region, markets in Australia, New Zealand, and Hong Kong are also closed for Boxing Day. Meanwhile, Indonesian markets remain closed following Christmas. However, markets in mainland China, Japan, South Korea, and India continue to operate, maintaining their regular trading schedules.Across the Atlantic, trading activities will resume today in North America and will proceed as usual until the New Year holiday in January. The Nasdaq Stock Exchange and the New York Stock Exchange (NYSE) were closed on December 25 in observance of Christmas.On Wall Street, major indexes finished higher in a shortened session on Christmas Eve Tuesday, primarily driven by gains in prominent tech stocks. The Dow Jones Industrial Average climbed by 0.9%, while the tech-focused Nasdaq Composite surged by 1.4%, marking a four-session winning streak and the onset of the Santa Claus rally. Meanwhile, the S&P 500 gained 1.1%, extending its positive run to three consecutive sessions.The material has been provided by InstaForex Company - www.instaforex.com
Philippines' Budget Balance Plunges to -213.0B in November 2024 - ForexTV
In a dramatic financial downturn, the Philippines' budget balance has swung from a modest surplus of 6.3 billion pesos in October 2024 to a significant deficit of -213.0 billion pesos the following month. This drastic change was officially updated on 26 December 2024.The shift marks a concerning development for the country's fiscal policy, reflecting potential challenges in revenue collection or increased government spending. The November 2024 figures point to the most substantial monthly deficit in recent records, raising questions about the economic strategy moving forward.As policymakers in the Philippines assess the implications of this abrupt fiscal change, eyes will be on the government's next steps to address the budgetary gap. Analysts will be closely watching economic reforms and budgetary policies, scrutinizing how they might steer the nation back toward financial stability in the months ahead. The data serves as a critical marker for economic management and may influence future fiscal decisions in the region.The material has been provided by InstaForex Company - www.instaforex.com
Singapore's Industrial Production Sees Robust Surge in November - ForexTV
Singapore's industrial production witnessed a remarkable upturn in November 2024, posting a significant increase with the indicator reaching 8.5%. This marks a substantial rise from October's figure of 1.2%, illustrating a strong recovery and growth in the sector. The latest update on this data came on December 26, 2024, providing insights into the country's production performance.This change represents a year-over-year comparison, indicating the acceleration of industrial activities compared to the same month in the previous year. Singapore's ability to achieve such a positive shift underscores its resilience and adaptability in the industrial sector.The strong performance in November is a promising sign for the country, suggesting that Singapore's industrial production is steadily gaining momentum as it moves towards the end of the year. This update will likely be met with optimism from stakeholders and policy-makers anticipating sustained progress into 2025.The material has been provided by InstaForex Company - www.instaforex.com
Japan's November Construction Orders Plummet by 10.2% Year-Over-Year - ForexTV
In a surprising turn of events, Japan's construction orders saw a significant downturn in November 2024, plunging by 10.2% on a year-over-year basis. This decline starkly contrasts the robust 44.6% increase reported in October 2024, offering a sobering outlook for the sector.This latest data, updated on December 26, 2024, marks a significant shift in momentum for Japan's construction industry, which had previously enjoyed substantial growth. The year-on-year analysis reveals that while October's figures were bolstered by a wave of projects and demand, November's downturn suggests underlying challenges that could signal cautionary winds ahead.The change from the previous month's zestful growth to the current decline underscores a volatile environment within the construction sector, prompting stakeholders to carefully assess the factors contributing to such abrupt shifts. Analysts are now scrutinizing potential causes, including economic fluctuations, policy adjustments, and resource availability, which may have influenced this marked downturn in Japan's construction orders for November. As the country navigates possible corrections, attention is keenly fixed on the steps that industry and policymakers will take to stabilize and rejuvenate the sector.The material has been provided by InstaForex Company - www.instaforex.com
DEMESNE RESOURCES LTD. ANNOUNCES CLOSING OF A THIRD TRANCHE OF PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT FINANCING - ForexTV
- NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES -Vancouver, BC, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Demesne Resources Ltd. (CSE:DEME) (OTCQB:DEMRF) (“Demesne” or the “Company”) is pleased to announce that it has completed the third tranche (the “Third Tranche”) of its previously announced non-brokered private placement financing (the “Offering”). Pursuant to the Third Tranche, the Company issued 1,660,000 common shares of the Company (“Common Shares”), at a price of $0.25 per Common Share for gross proceeds of approximately $415,000. The Company plans to complete a subsequent tranche of the Offering, for gross proceeds of up to $424,599 in January 2025. In connection with the Third Tranche, the Company paid finder’s fees to eligible finders consisting of $17,150 in cash and 68,600 Common Share purchase warrants (the “Finder’s Warrants”). Each Finder’s Warrant is exercisable to acquire one Common Share of capital of the Company at an exercise price of $0.25 per Common Share for a period of 12-months. Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the Canadian Securities Exchange (the “CSE”). The Company will use the net proceeds from the Offering to fund certain payments pursuant to an option agreement in connection with the IMA Mine Project, certain payments pursuant to an option agreement in connection with the Star Project, work program related expenses, marketing expenses, and for general working capital purposes. All securities issued in connection with the Third Tranche are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. ABOUT DEMESNE RESOURCES LTD. Demesne Resources Ltd. is a British Columbia based company involved in the acquisition and exploration of magnetite mineral properties. The Company's Star Project consists of five contiguous mineral titles covering an area of approximately 4,615.75 hectares located in the Skeena Mining Division, British Columbia, Canada. The Company has entered into an option agreement pursuant to which it is entitled to earn an undivided 100% interest in the Star Project. Demesne has also entered into an option agreement, pursuant to which it can acquire a 100% interest (subject to a 2% royalty) in and to the IMA Mine Project, a past producing underground tungsten mine situated on 22 patented claims located in East Central, Idaho, United States. Social media links: LinkedIn: https://www.linkedin.com/company/demesneresources/ X: https://x.com/demesneresource Facebook: https://www.facebook.com/DemesneResources Instagram: https://www.instagram.com/demesneresources/ YouTube: https://www.youtube.com/@demesneresources ON BEHALF OF THE BOARD OF DIRECTORS: Murray Nye CEO1055 West Georgia Street, Suite 1500Vancouver, BC V6E 0B6Canada For further information, please contact: Murray Nye, CEOEmail: ir@demesneresources.comPhone: +1 (416) 300-7398 CSE:DEMEOTCQB:DEMRF The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release. This press release includes "forward-looking information" that is subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations. CONTACT: Holly Iervella
Mosaic Announces Company Updates - ForexTV
MONTREAL, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “the Company”) announces some updates about the Company and takes this opportunity to thank its shareholders, partners and suppliers for their trust throughout 2024 and wishes them a Merry Christmas and a Happy New Year 2025. Mirabelli and Maqua Results The Company announces that it has received all its results related to the summer and fall 2024 exploration campaigns on the Mirabelli SM and Maqua SM properties. These do not reveal any significant grades in the metals and minerals initially sought. Management announces that exploration work will not be continued on these properties. The Company also announces that it no longer intends to continue exploration related to Lithium and will focus on the gold potential of its properties, in particular, the Amanda project now 100% owned and which contains numerous gold showings. Lichen and 113 North Projects Mosaic announces that it has received formal notification from Castlebar Capital Corporation that it is abandoning the option agreement to acquire 100% of the Lichen property (see press release dated June 11, 2024). Mosaic is regaining control of this property which consists of 282 claims covering a total area of 15,622 hectares and is located approximately 100 km west of the Chibougamau mining camp. The property is underlain by volcanic rocks of the Obatogamau Formation intersected by intermediate stocks and plutons. The volcanic belt parallels two known gold-bearing volcanic belts, the Bachelor Lake gold zone to the west and the Osisko-Windfall gold zone to the south. The Nelligan and Monster Lake gold projects are located at the eastern end of the volcanic belt. The Company also announces that it has received formal notification from Panther Minerals Inc. (formerly Lithium Lion Metals Inc.) that the latter is abandoning the option agreement to acquire 100% of the 113 North property (see press release dated December 5, 2023). Mosaic is regaining control of this property which is located in the southeastern part of the Abitibi Greenstone Belt and comprises 59 cells totaling 3,010 hectares within a 6- to 12-kilometre-wide band of volcano-sedimentary rocks located between the Josselin and Montgay granodiorite-tonalite batholiths. The volcanic rocks in this group have felsic, intermediate and mafic compositions and are cut by dunite, gabbro and diorite dykes. Iron formations (sulphides and oxides) and clastic sedimentary rocks, such as greywackes and schists, are also present. Gold, copper, nickel, platinum and palladium occurrences have been discovered in this geological environment near the project. The scientific and technical information of Mosaic Minerals Corporation included in this press release has been reviewed and approved by Gilles Laverdière, P.Geo, Vice-President Exploration of Mosaic Minerals and qualified person under National Instrument 43-101 respecting information concerning mining projects (“Regulation 43-101”). About Mosaic Minerals Corporation Mosaic Minerals Corp. is a Canadian mining exploration company listed on the Canadian Securities Exchange (CSE: MOC) focusing on the exploration of critical minerals such as Nickel in the province of Quebec. Source:M. Jonathan Hamel President & CEOjhamel@mosaicminerals.ca This release contains certain “forward-looking information” under applicable Canadian securities laws concerning the Arrangement. Forward-looking information reflects the Company’s current internal expectations or beliefs and is based on information currently available to the Company. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “projects”, “potential”, “scheduled”, “forecast”, “budget” or the negative of those terms or other comparable terminology. Assumptions upon which such forward-looking information is based includes, among others, that the conditions to closing of the Arrangement will be satisfied and that the Arrangement will be completed on the terms set out in the definitive agreement. Many of these assumptions are based on factors and events that are not within the control of the Company, and there is no assurance they will prove to be correct or accurate. Risk factors that could cause actual results to differ materially from those predicted herein include, without limitation: that the remaining conditions to the Arrangement will not be satisfied; that the business prospects and opportunities of the Company will not proceed as anticipated; changes in the global prices for gold or certain other commodities (such as diesel, aluminum and electricity); changes in U.S. dollar and other currency exchange rates, interest rates or gold lease rates; risks arising from holding derivative instruments; the level of liquidity and capital resources; access to capital markets, financing and interest rates; mining tax regimes; ability to successfully integrate acquired assets; legislative, political or economic developments in the jurisdictions in which the Company carries on business; operating or technical difficulties in connection with mining or development activities; laws and regulations governing the protection of the environment; employee relations; availability and increasing costs associated with mining inputs and labour; the speculative nature of exploration and development; contests over title to properties, particularly title to undeveloped properties; and the risks involved in the exploration, development and mining business. Risks and unknowns inherent in all projects include the inaccuracy of estimated reserves and resources, metallurgical recoveries, capital and operating costs of such projects, and the future prices for the relevant minerals. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release. NOT FOR DISTRIBUTION IN THE UNITED STATES OR ANY US NEWS WIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE TITLES DESCRIBED HEREIN. CONTACT: Source: M. Jonathan Hamel President & CEO jhamel@mosaicminerals.ca
GA (Int’l) Capital Management Limited Announces to Support Explosive Growth in the eVTOL Sector in 2025 - ForexTV
HONG KONG, Dec. 25, 2024 (GLOBE NEWSWIRE) -- GA (Int’l) Capital Management Limited, a global investment firm recognized for its innovative strategies and forward-thinking portfolio, has announced its decision to back the electric vertical takeoff and landing (eVTOL) industry, positioning itself to capitalize on the sector's anticipated explosive growth in 2025 and beyond. The eVTOL sector, widely considered one of the most transformative advancements in aviation, is poised for a major leap forward in the coming years. With the global shift towards sustainable mobility, the rapid advancements in battery technology, and a growing interest in urban air mobility, eVTOL is primed to revolutionize transportation, particularly in urban areas where traffic congestion and pollution are becoming critical challenges. As a leading player in global capital management, GA (Int’l) Capital Management Limited recognizes the massive potential of the eVTOL sector to redefine transportation systems and contribute to the broader goal of decarbonization. This visionary sector is expected to lead to cleaner, faster, and more efficient urban travel solutions, offering an alternative to traditional ground-based transportation and creating new opportunities for growth in aerospace, manufacturing, and technology. "We are excited to back the eVTOL sector as part of our long-term investment strategy. The convergence of sustainability goals, advanced technologies, and a desire for faster, smarter transportation solutions makes the eVTOL industry a key driver of change in the coming decade," said Clive Mantle, Director of Institutional Trading at GA (Int’l) Capital Management Limited. "We believe that 2025 will be a landmark year for eVTOL technology, with advancements in safety, infrastructure, and regulatory frameworks making widespread adoption possible. Our support for this sector is a testament to our commitment to investing in innovative technologies that will shape the future of transportation." GA (Int’l) Capital Management Limited's decision to invest in eVTOL is underscored by the company's track record of strategic investments in cutting-edge industries, particularly those at the intersection of sustainability, technology, and scalability. With global markets increasingly demanding eco-friendly alternatives to traditional transportation, GA (Int’l) sees eVTOL as a critical component in creating a more sustainable and efficient future. The firm's investment will focus on key players within the eVTOL ecosystem, including manufacturers, infrastructure developers, and technology innovators. The firm believes that its support will help accelerate the pace of development in the industry, ensuring that the sector reaches its full potential in terms of safety, performance, and mass-market adoption. 2025 is expected to be a breakthrough year for the eVTOL sector, as several companies are set to bring their electric aircraft to market, supported by rigorous regulatory approvals and advanced safety standards. This aligns with the growing demand for urban air mobility solutions, particularly in major metropolitan areas, where eVTOL aircraft can alleviate traffic congestion, reduce emissions, and provide faster, more efficient routes for passengers. As part of its investment strategy, GA (Int’l) Capital Management Limited will continue to work closely with eVTOL startups, aerospace companies, and technology developers to help ensure the sector's growth trajectory is both profitable and sustainable. Through this initiative, GA (Int’l) aims to play a pivotal role in the ongoing evolution of the transportation industry. About GA (Int’l) Capital Management Limited GA (Int’l) Capital Management Limited is a leading global investment firm focused on high-growth sectors, sustainable technologies, and innovative solutions. Known for its comprehensive and forward-thinking investment strategies, a portfolio that spans industries such as clean energy, aerospace, and digital infrastructure, and a commitment to creating long-term value, the firm strives to drive innovation while maintaining a strong focus on sustainability and social impact. For inquiries, please contact: Clive Mantle Director of Institutional Trading GA (Int’l) Capital Management Limited Email: clive.mantle@gacapitalm.com Phone: +852 3002 3446 Website: https://gacapitalm.com/ Disclaimer: This content is provided by the GA (Int’l) Capital Management Limited. The statements, views, and opinions expressed in this column are solely those of the content provider. The information shared in this press release is not a solicitation for investment, nor is it intended as investment, financial, or trading advice. It is strongly recommended that you conduct thorough research and consult with a professional financial advisor before making any investment or trading decisions. Please conduct your own research and invest at your own risk. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/15cc760b-4a84-40dc-8b25-d5432262ca0c
Immutable Announcement: If You Have Suffered Losses in IMX Tokens, You Are Encouraged to Contact The Rosen Law Firm About Your Rights - ForexTV
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims against Immutable resulting from allegations that Immutable may have issued materially misleading business information to the investing public. So what: If you purchased IMX tokens you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=31342 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. What is this about: On November 1, 2024, Immutable revealed the Securities and Exchange Commission (“SEC”) had filed a Wells Notice to Immutable over its sales of IMX tokens. Immutable believes the SEC “are targeting the listing and private sales of IMX in 2021.” Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA - ForexTV
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Cassava’s drug prospects and anticipated growth while also minimizing risk from a potential drug failure. Yet, in truth, Cassava’s repeated statements of confidence in simufilam, Cassava’s leading drug candidate, and reliance upon spinning the statistically insignificant data from the Phase 2 study fell short of the reality of simufilam’s potential; Cassava simply did not have a drug that was capable of abating the progression of Alzheimer’s Disease, even when attempting to treat only the mild and moderate cases. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com
Opus One Gold Corporation Announces Closing of Private Placement - ForexTV
MONTREAL, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Opus One Gold Corporation (OOR: TSXV) (“Opus One Gold” or the “Company”), is pleased to announce the closing of a non-brokered private placement of flow-through shares (“FT Shares”) and units of the Company (the “Units”) for aggregate gross proceeds of $1,495,750 (the “Offering”). In total, the Company issued 25,104,545 FT Shares for gross proceeds of $1,380,750 at a price per FT Share of $0.055 and 2,300,000 Units for gross proceeds of $115,000 at a price per Unit of $0.05, with each Unit being comprised of one common share of the Company (a “Share”) and one common share purchase warrant (each a “Warrant”, and together, the “Warrants”), with each Warrant entitling the holder to acquire one common share (each a “Warrant Share”) at an exercise price of $0.10 per Share for a period of 36 months following the closing of the Offering. The gross amount raised from the issuance of FT Shares will be used by the Company for exploration on its mineral exploration properties and the net proceeds raised from the issuance of Units will be used for general working capital of the Company and payment of fees related to the Offering. The FT Share and Units were offered by way of the “accredited investor” exemption under National Instrument 45-106 – Prospectus Exemptions in all the provinces of Canada. The Units, FT Shares, Shares, Warrants and Warrant Shares are subject to a four-month hold period in Canada following the closing of the Offering. In aggregate, the Company paid 8% in cash finders fees and issued a total of 363,636 compensation warrants to arm’s length finders, with each such compensation warrant being exercisable for a period of 24 months following the closing at a price of $0.055 per Share. Closing is subject to the approval of the TSX Venture Exchange and other customary closing conditions. Related Party Transaction Patrick Fernet, a director of the Company, acquired 600,000 FT Shares for total consideration of $33,000. Patrick Fernet is hereinafter referred to as the “Insider”. The Insider is considered a “related party” and “insider” of the Company for the purposes of applicable securities laws and stock exchange rules. The subscription and issuance of FT Shares by the Insider constitutes a related party transaction but is exempt from the formal valuation and minority approval requirements of Regulation 61-101 - Protection of Minority Security Holders in Special Transactions as neither the fair market value of the common shares issued to the Insider, nor the consideration paid by such Insider, exceeds 25% of the Company’s market capitalization. The Insider abstained from voting on all matters relating to the Offering. Clarification regarding previous private placement On August 12th and September 11th, 2024, the Company announced the closing of a previous private placement of units of the company. The Company wishes to clarify the intended use of the net proceeds raised from said private placement, being $361,000, as follows (noting that no amount was payable to investor relations service providers, and less than 10% was payable to non-arm’s length parties): USE OF PROCEEDS$Total 361,000 Management (CEO &CFO) 36,000Professional fees 75,000Regulatory fees 25,000Office and administration 25,000Working capital 200,000 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release. ABOUT OPUS ONE GOLD CORPORATION Opus One Gold Corporation is a mining exploration company focused on discovering high quality gold and base metals deposits within strategically located properties in proven mining camps, close to existing mines in the Abitibi Greenstone Belt, north-western Quebec and north-eastern Ontario - one of the most prolific gold mining areas in the world. Opus One holds assets in Val-d'Or and Matagami areas. For more information, please contact: Louis MorinChief Executive Officer & Director Tel.: (514) 591-3988 Michael W. Kinley, CPA, CAPresident, Chief Financial Officer & Director Tel: (902) 402-0388 info@OpusOneGold.com Visit Opus One’s website: www.OpusOneGold.com
Southwest Airlines Co. Announcement: Southwest Airlines Co. Investors Are Encouraged to Contact The Rosen Law Firm About Ongoing Investigation of Breaches of Fiduciary Duties by the Directors and Officers – LUV - ForexTV
NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Southwest Airlines Co. (NYSE: LUV) in connection with Southwest Airlines’ information technology infrastructure impacting Southwest Airlines’ business, operations, and stock price. If you currently own shares of Southwest Airlines stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=10716 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com
AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption – Hagens Berman - ForexTV
SAN FRANCISCO, Dec. 24, 2024 (GLOBE NEWSWIRE) -- AstraZeneca, the British-Swedish pharmaceutical giant, is facing a securities class action lawsuit in the U.S. alleging the company misled investors about its business practices in China, a critical market that accounts for roughly 13% of its revenue. Hagens Berman has opened an investigation and urges investors in AstraZeneca American Depositary Shares who suffered substantial losses to submit your losses now. Class Period: Feb. 23, 2022 – Dec. 17, 2024Lead Plaintiff Deadline: Feb. 21, 2025Visit: www.hbsslaw.com/investor-fraud/azn Contact the Firm Now: AZN@hbsslaw.com 844-916-0895 AstraZeneca (AZN) Securities Fraud Class Action: The lawsuit, filed in the U.S. District Court for the Central District of California, claims AstraZeneca made false and misleading statements and omitted material information regarding the company's exposure to legal and regulatory risks in China. Specifically, the complaint alleges that AstraZeneca: Engaged in insurance fraud in China.Faced heightened legal exposure in China, culminating in the detention of Leon Wang, Executive Vice President International and AstraZeneca China President, by Chinese law enforcement authorities. Understated the significant legal and regulatory risks associated with its China operations.Failed to disclose that these issues could materially harm its business activities and financial performance in China. The lawsuit highlights a series of events that began to unfold in late October 2024. On October 30th, AstraZeneca announced that Mr. Wang was cooperating with an ongoing investigation by Chinese authorities, without providing further details. This news sent AstraZeneca's share price down by approximately 3%. On November 5th, the Chinese business news outlet Yicai reported that dozens of AstraZeneca China executives had been implicated in the investigation, with some facing prison sentences exceeding 10 years. Yicai also cited an industry insider who attributed the company's compliance issues to "extreme pressure" placed on sales representatives to meet ambitious sales targets. This news further impacted AstraZeneca's stock price, causing a decline of around 7%. On November 12th, AstraZeneca confirmed Mr. Wang's detention and disclosed that the PRC investigation included allegations of medical insurance fraud, illegal drug importation, and personal information breaches. More recently, on December 18th, the Financial Times reported that AstraZeneca executives anticipate a revenue decline in China due to the arrests of Mr. Wang and other senior executives. The report cited an AstraZeneca executive who stated that "doctors are unwilling to interact with our salespeople and prescribe our medicines" following the investigation. This news resulted in a nearly 4% drop in AstraZeneca's share price. “If the allegations are substantiated, we believe AstraZeneca failed to adequately disclose the company’s exposure for its operations in China,” said Reed Kathrein, an attorney leading the firm's investigation. If you invested in AstraZeneca and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now » If you’d like more information and answers to frequently asked questions about the AstraZeneca investigation, read more » Whistleblowers: Persons with non-public information regarding AstraZeneca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email AZN@hbsslaw.com. About Hagens BermanHagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895
Verde Announces CEO's Decision to End Automatic Securities Disposition Plan - ForexTV
SINGAPORE, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd. (TSX: “NPK”) (OTCQX: “VNPKF”) ("Verde” or the “Company”) announces that its President and Chief Executive Officer, Cristiano Veloso, has terminated the automatic securities disposition plan (the "ASDP") previously announced in the Company's press release dated September 28, 2023.1 Mr. Veloso was not in possession of material non-public information at the time the securities broker was provided with notice to terminate the ASDP. In accordance with the terms of the ASDP, the termination will become effective on January 24, 2025, being 30 days following the date notice of termination was provided. This decision relates to personal financial planning and confirms Mr. Veloso’s confidence in the company’s future prospects. About Verde AgriTech Verde AgriTech is dedicated to advancing sustainable agriculture through the innovation of specialty multi-nutrient potassium fertilizers. Our mission is to increase agricultural productivity, enhance soil health, and significantly contribute to environmental sustainability. Utilizing our unique position in Brazil, we harness proprietary technologies to develop solutions that not only meet the immediate needs of farmers but also address global challenges such as food security and climate change. Our commitment to carbon capture and the production of eco-friendly fertilizers underscores our vision for a future where agriculture contributes positively to the health of our planet. Cautionary Language and Forward-Looking Statements All Mineral Reserve and Mineral Resources estimates reported by the Company were estimated in accordance with the Canadian National Instrument 43-101 and the Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards (May 10, 2014). These standards differ significantly from the requirements of the U.S. Securities and Exchange Commission. Mineral Resources which are not Mineral Reserves do not have demonstrated economic viability. This document contains "forward-looking information" within the meaning of Canadian securities legislation and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. This information and these statements, referred to herein as "forward-looking statements" are made as of the date of this document. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to: (i) the estimated amount and grade of Mineral Resources and Mineral Reserves; (ii) the estimated amount of CO2 removal per ton of rock; (iii) the PFS representing a viable development option for the Project; (iv) estimates of the capital costs of constructing mine facilities and bringing a mine into production, of sustaining capital and the duration of financing payback periods; (v) the estimated amount of future production, both produced and sold; (vi) timing of disclosure for the PFS and recommendations from the Special Committee; (vii) the Company’s competitive position in Brazil and demand for potash; (viii) estimates of operating costs and total costs, net cash flow, net present value and economic returns from an operating mine. (ix) the expected terms of the debt restructuring; (x) the expected financial impact of the debt restructuring to the Company; (xi) the timeline for court approval of the debt restructuring; and (xii) the potential arising from the re-assaying of certain core samples. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as "expects", "anticipates", "plans", "projects", "estimates", "envisages", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements. All forward-looking statements are based on Verde's or its consultants' current beliefs as well as various assumptions made by them and information currently available to them. The most significant assumptions are set forth above, but generally these assumptions include, but are not limited to: (i) the presence of and continuity of resources and reserves at the Project at estimated grades; (ii) the estimation of CO2 removal based on the chemical and mineralogical composition of assumed resources and reserves; (iii) the geotechnical and metallurgical characteristics of rock conforming to sampled results; including the quantities of water and the quality of the water that must be diverted or treated during mining operations; (iv) the capacities and durability of various machinery and equipment; (v) the availability of personnel, machinery and equipment at estimated prices and within the estimated delivery times; (vi) currency exchange rates; (vii) Super Greensand® and K Forte® sales prices, market size and exchange rate assumed; (viii) appropriate discount rates applied to the cash flows in the economic analysis; (ix) tax rates and royalty rates applicable to the proposed mining operation; (x) the availability of acceptable financing under assumed structure and costs; (xi) anticipated mining losses and dilution; (xii) reasonable contingency requirements; (xiii) success in realizing proposed operations; (xiv) receipt of permits and other regulatory approvals on acceptable terms; and (xv) the fulfilment of environmental assessment commitments and arrangements with local communities. Although management considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect. Many forward-looking statements are made assuming the correctness of other forward looking statements, such as statements of net present value and internal rates of return, which are based on most of the other forward-looking statements and assumptions herein. The cost information is also prepared using current values, but the time for incurring the costs will be in the future and it is assumed costs will remain stable over the relevant period. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. We caution readers not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates assumptions and intentions expressed in such forward-looking statements. These risk factors may be generally stated as the risk that the assumptions and estimates expressed above do not occur as forecast, but specifically include, without limitation: risks related to the court approval process for the debt restructuring; risks relating to variations in the mineral content within the material identified as Mineral Resources and Mineral Reserves from that predicted; variations in rates of recovery and extraction; the geotechnical characteristics of the rock mined or through which infrastructure is built differing from that predicted, the quantity of water that will need to be diverted or treated during mining operations being different from what is expected to be encountered during mining operations or post closure, or the rate of flow of the water being different; developments in world metals markets; risks relating to fluctuations in the Brazilian Real relative to the Canadian dollar; increases in the estimated capital and operating costs or unanticipated costs; difficulties attracting the necessary work force; increases in financing costs or adverse changes to the terms of available financing, if any; tax rates or royalties being greater than assumed; changes in development or mining plans due to changes in logistical, technical or other factors; changes in project parameters as plans continue to be refined; risks relating to receipt of regulatory approvals; delays in stakeholder negotiations; changes in regulations applying to the development, operation, and closure of mining operations from what currently exists; the effects of competition in the markets in which Verde operates; operational and infrastructure risks and the additional risks described in Verde's Annual Information Form filed with SEDAR in Canada (available at www.sedar.com) for the year ended December 31, 2023. Verde cautions that the foregoing list of factors that may affect future results is not exhaustive. When relying on our forward-looking statements to make decisions with respect to Verde, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Verde does not undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by Verde or on our behalf, except as required by law. For additional information please contact: Cristiano Veloso, Chief Executive Officer and Founder Tel: +55 (31) 3245 0205; Email: investor@verde.ag www.verde.ag | www.investor.verde.ag ________________________ 1 See: https://investor.verde.ag/automatic-securities-disposition-plan-established-by-verde-agritech-chief-executive-officer-2/
BoJ Core CPI Rises to 1.7%, Signaling Persistent Inflationary Pressures in Japan - ForexTV
The latest data released on December 24, 2024, reveals that Japan's core Consumer Price Index (CPI) has increased by 1.7% year-over-year. This marks an uptick from the previous figure of 1.5%, indicating a slight but notable rise in core inflation.Japan's core CPI, which excludes often-volatile fresh food prices but still includes energy, is a vital indicator the Bank of Japan (BoJ) closely monitors to gauge underlying inflation trends. The recent increase suggests persistent inflationary pressures within the Japanese economy, coming at a time when global inflation has been a significant concern. This rise in core CPI reflects changes in price levels compared to the same period a year ago, highlighting ongoing shifts in consumer prices amid economic recovery efforts.The modest rise may bolster the BoJ's strategy of maintaining its ultra-loose monetary policy and yield curve control measures to foster economic resilience. However, the central bank will likely remain vigilant of any potential price instability as it continues to navigate the complex post-pandemic economic landscape. With inflation edging upwards, the BoJ may face growing scrutiny regarding its readiness to adjust its policy toolkit if inflation accelerates beyond its target range. Investors and policymakers alike will be keenly observing these developments as they shape future economic trajectories for Japan.The material has been provided by InstaForex Company - www.instaforex.com
Correction: Invesco Ltd: Form 8.3 - International Paper Company; Public dealing disclosure - ForexTV
Amendment: This is an amendment to the form submitted on 23.12.2024 at 14:33. Amendment has been done in Section 2(a) & 3(a) of the form. FORM 8.3 PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.KEY INFORMATION (a)Full name of discloser:Invesco Ltd. (b)Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offereeInternational Paper Company (d)If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e)Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable date prior to the disclosure20.12.2024 (f)In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?If it is a cash offer or possible cash offer, state “N/A”Yes, Smith (DS) PLC 2.POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a)Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:Common stock US4601461035 InterestsShort Positions Number%Number% (1)Relevant securities owned and/or controlled:7,935,520*2.28 (2)Cash-settled derivatives: (3)Stock-settled derivatives (including options) and agreements to purchase/sell: Total7,935,520*2.28 *The change in the holding of 12,730 shares since the last disclosure on 20.12.2024 is due to the transfer in of a discretionary holding at 54.45 USD. All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b)Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated. (a)Purchases and sales Class of relevant securityPurchase/saleNumber of securitiesPrice per unit Common stock US4601461035Sale4553.87 USD Common stock US4601461035Sale306,13854.45 USD Common stock US4601461035Purchase10054.38 USD Common stock US4601461035Sale25654.37 USD Common stock US4601461035Purchase35,51954.45 USD Common stock US4601461035Sale482,81153.90 USD Common stock US4601461035Purchase0454.12 USD Common stock US4601461035Sale4,20454.23 USD (b)Cash-settled derivative transactions Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit (c)Stock-settled derivative transactions (including options) (i)Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit (ii)Exercise Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (d)Other dealings (including subscribing for new securities) Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable) 4.OTHER INFORMATION (a)Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” None (b)Agreements, arrangements, or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” None Is a Supplemental Form 8 (Open Positions) attached?NO Date of disclosure24.12.2024 Contact namePhilippa Holmes Telephone number+441491417447 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Netherlands Sees GDP Growth Surge to 1.7% in Third Quarter 2024 - ForexTV
In a promising economic development, the Netherlands has witnessed a notable increase in its GDP growth for the third quarter of 2024, with the figure reaching 1.7%. This marks a significant improvement from the previous quarter, where the GDP growth rate was recorded at 0.8%, indicating robust year-over-year economic performance.The GDP growth acceleration can be seen as a reflection of strengthening economic activities as compared to the same period last year. The reported figures, updated on December 24, 2024, suggest an emerging positive trend in the Dutch economy, hinting at potential stability and resilience amid global economic challenges.Analysts are optimistic that this upward trajectory could signal a broader recovery for the Netherlands, as the country continues to navigate complex economic landscapes and seeks to enhance its economic output during the coming quarters. This favorable economic indicator may provide a boost to both investor confidence and market sentiments in the Netherlands moving forward.The material has been provided by InstaForex Company - www.instaforex.com
Faircourt Asset Management Inc. Announces December Distribution - ForexTV
Toronto, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Faircourt Asset Management Inc., as Manager of the Faircourt Fund (NEO:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund. Faircourt FundsTrading SymbolDistribution Amount (per share/unit)Ex-Dividend DateRecord DatePayable DateFaircourt Gold Income Corp.FGX$0.024December 31, 2024December 31, 2024January 15, 2025 Faircourt Asset Management Inc. is the Investment Advisor for Faircourt Gold Income Corp. This press release is not for distribution in the United States or over United States wire services. For further information on the Faircourt Funds, please visit www.faircourtassetmgt.com or please contact 1-800-831-0304. You will usually pay brokerage fees to your dealer if you purchase or sell Shares of the Fund on the NEO Exchange or other alternative Canadian trading system (an “exchange”). If the Shares are purchased or sold on an exchange, investors may pay more than the current net asset value when buying Shares of the Fund and may receive less than the current net asset value when selling them. There are ongoing fees and expenses associated with owning units of an investment fund. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in the public filings available at www.sedar.com. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.
Blockmate Ventures Announces Closing of Strategic Investment and Incentive Grant - ForexTV
TORONTO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Blockmate Ventures Inc. (TSX.V: MATE) (OTCQB: MATEF) (FSE: 8MH1) (“Blockmate” or the “Company”) is pleased to announce that it has closed its strategic investment (the “Offering”) involving a group of strategic investors led by Antanas Guoga (Tony G) for gross proceeds of $1,400,000. This strategic funding supports Blockmate’s pursuit of industry leadership in blockchain innovation and underscores our commitment to sustainable and transformative technology. In connection with completion of the Offering, the Company has issued 14,000,000 units (each, a “Unit”) at a price of $0.10 per Unit. Each Unit consists of one common share, and one common share purchase warrant exercisable to acquire a further common share at a price of $0.50 until December 23, 2027. All securities issued in connection with the Offering are subject to statutory restrictions on resale until April 24, 2025, in accordance with applicable securities laws. In addition, Tony G has voluntarily agreed to restrict resale of the 10,000,000 Units he acquired in the Offering until December 23, 2025. No finders’ fees or commissions were paid by the Company in connection with completion of the Offering. Incentive Grant The Company also announces that it has granted 5,275,000 incentive stock options (the “Options”), 1,200,000 restricted share units (the “RSUs”) and 5,000,000 deferred share units (the “DSUs”) in accordance with its omnibus incentive plan (the “Incentive Plan”) adopted by shareholders at the annual general and special meeting held on November 23, 2023. 625,000 of the Options vest immediately and are exercisable at a price of $0.21 for a period of thirty-six months. The remaining 5,000,000 Options vest quarterly over a twenty-four month period, and are exercisable at a price of $0.21 for a period of forty-eight months. The RSUs vest and will be settled in common shares of the Company after twelve months. The DSUs vest after twelve months but will only be settled in common shares of the Company upon the departure of the holder from the Company. 2,725,000 of the Options and all of the DSUs exceed the available room under the Incentive Plan. The Company intends to seek approval of shareholders to increase the size of the Incentive Plan at the next annual general meeting and will at that time seek ratification from shareholders for the additional Options and the DSUs. Until such time as shareholder ratification has been received, the additional Options and DSUs will not vest and will not be eligible for exercise or settlement. In the event shareholders elect not to ratify the grant, and room within the Incentive Plan is not available at the time, the additional Options and DSUs will be cancelled. Early Warning Disclosure In connection with the incentive grant, Domenic Carosa, a director of the Company, has been issued 5,000,000 Options and 5,000,000 DSUs. Prior to the grant, Mr. Carosa controlled 17,252,400 common shares, 1,500,000 incentive stock options, and 3,000,000 common share purchase warrants, of the Company, all of which are held by Carosa Corporation B.V., a holding company controlled by Domenic Carosa. The common shares controlled by Mr. Carosa prior to the grant represent approximately 15.1% of the issued and outstanding common shares of the Company. Following the grant, Mr. Carosa has control and direction over 17,252,400 common shares, 6,500,000 Options, 3,000,000 common share purchase warrants and 5,000,000 DSUs of the Company. Assuming the exercise and conversion of all of the Options, share purchase warrants and DSUs controlled by Mr. Carosa, he would have control and direction over 31,752,400 common shares of the Company representing approximately 19.8% of the then outstanding common shares of the Company. Mr. Carosa has acquired the securities for investment purposes and in connection with his compensation as a director of the Company and, as disclosed in the accompanying Early Warning Report, may in the future acquire or dispose of securities of the Company, through the market, privately or otherwise, as circumstances or market conditions warrant. A copy of the Early Warning Report filed with the applicable securities regulators regarding the above acquisition will be available under the profile for the Company on SEDAR+ (www.sedarplus.ca). About Blockmate Ventures Inc.Blockmate is a venture creator focussing on building fast-growing technology businesses relating to cutting edge sectors such as blockchain and renewable energy. Working with prospective founders, projects in incubation can benefit from the Blockmate ecosystem that offers tech, services, integrations and advice to accelerate the incubation of projects towards monetization. Recent projects include Hivello (download our free passive income app at www.hivello.com) and Sunified, digitising solar energy. The leadership team at Blockmate have successfully founded successful tech companies from the Dotcom era through to the social media era. Learn more about being a Blockmate at: www.blockmate.com/. Blockmate welcomes investors to join the Company’s mailing list for the latest updates and industry research by subscribing at https://www.blockmate.com/subscribe. ON BEHALF OF THE BOARD OF DIRECTORS Justin Rosenberg, Chief Executive OfficerBlockmate Ventures Inc.justin@blockmate.com(+1-580-262-6130) Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release Forward-Looking InformationThis news release contains “forward-looking statements” or “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on the assumptions, expectations, estimates and projections as of the date of this news release. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Raindrop disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by applicable securities laws. Readers should not place undue reliance on forward-looking statements.
Dutch Economy at a Standstill: GDP Growth Remains Unchanged in Q3 2024 - ForexTV
The Dutch economy has shown signs of stagnation as the GDP growth for the third quarter of 2024 has halted, once again registering no change at 0.8% quarter-on-quarter. This latest release, updated on December 24, 2024, reflects an identical growth rate to that of the previous quarter, indicating a period of economic steadiness without acceleration or decline.The consistent GDP performance indicates a stable economic environment for the Netherlands, as the country navigates through a quarter-over-quarter analysis. While the economy has not contracted, the static growth figure suggests potential challenges in stimulating further expansion. Stakeholders in the financial and business sectors may now be looking towards policy adjustments or market innovations to invigorate growth going forward.As the data indicates unchanged economic growth for two consecutive quarters, attention will likely shift to how Dutch economic strategies or external factors might influence future GDP trajectories. The outcomes in upcoming quarters will be critical in determining whether the Netherlands can maintain this stable growth or if new strategies will be essential to revitalize economic dynamics.The material has been provided by InstaForex Company - www.instaforex.com
CoinEx Celebrates 7th Anniversary: CEO Shares Milestones and Future Plans in Recent AMA - ForexTV
HONG KONG, Dec. 24, 2024 (GLOBE NEWSWIRE) -- On Dec 23, 2024, CoinEx celebrated its 7th year anniversary with a special AMA (Ask Me Anything) session on Telegram. This specific event drew the attention of crypto enthusiasts, users, and the CoinEx leadership. The whole session was to reflect on the platform’s achievements, challenges, and plans for the future. Through CoinEx’s CEO’s guide, the AMA session explored deeply into how the platform has grown, its new ideas, and its strong focus on user-friendly values. Here’s a summarized version of the session, highlighting key takeaways from CoinEx’s journey and its plans for the years ahead. From the CEO’s reflections on the company’s development to the core philosophy that drives CoinEx’s success, here’s an in-depth look at the event. Reflecting on 7 Years of Excellence CoinEx's narrative over the last seven years has been one of perseverance, creativity, and adaptability. The CEO opened the AMA by discussing the company's path through market volatility and industry hurdles, emphasizing how these events developed CoinEx into the platform it is today. Milestones That Define CoinEx CoinEx’s evolution is characterized by groundbreaking achievements: A Comprehensive Ecosystem: CoinEx has built a big ecosystem with different parts like CoinEx Wallet, CoinEx Smart Chain, and CoinEx Charity.Product Iteration and Innovation: In last two years, CoinEx has finished more than 150 upgrades. These features include the introduction of CoinEx Staking, PreToken Trading, and P2P services. Each one is made to give users more options and freedom in their trading and investment experiences.Global Reach & Growth: CoinEx now has over 10 million registered users from more than 200 countries and regions all around the world. The platform supports 18 languages, enabling seamless interaction for users worldwide.Unshaken commitment to Security: CoinEx has always had a resolve to ensure utmost safety for its clients. That includes using top-notch security systems such as proof of reserves, an asset safety system, and a user protection fund.Of course, all these wouldn’t have happened if it were not for the support of CoinEx users worldwide. 2024: A Year of Breakthroughs When asked to summarize 2024 in one word, the CEO chose “breakthrough.” This year marked significant progress in various areas, setting the stage for future growth. Record Growth across the Board User Base Expansion: CoinEx’s registered user base surpassed 10 million, doubling from the previous year. The platform expanded its services to new regions, adding two additional language markets.CET Ecosystem Success: CoinEx’s native token, CET, experienced a remarkable surge in recognition and value, crossing the $0.1 mark to reach a three-year high.Innovative Products: Platforms like CoinEx Insight, CoinEx Feed, and CoinEx Academy have published over 2,500 pieces of educational content, helping users expand their crypto knowledge.Educating the Public: Platforms like CoinEx Insight, CoinEx Feed, and CoinEx Academy have published over 2,500 pieces of educational content, helping users expand their crypto knowledge.Through these initiatives, CoinEx has demonstrated its ability to adapt to market demands while maintaining a clear focus on user needs and technological advancements. The “User-First” Philosophy CoinEx consistently upholds its “user-first” philosophy by engaging with users through diverse interactive methods to listen to and address their feedback. The crypto exchange supports 18 languages to ensure global users can easily access assistance. What’s more, CoinEx’s customer service team promptly responds to user inquiries and feedback, improving satisfaction while collecting valuable user opinions and suggestions. The company has also actively built and maintained user communities, leveraging social media, forums, and online discussion groups to stay closely connected with users, understand their needs, and adjust accordingly. And when it comes to localized services, CoinEx has assembled an international team to ensure users in different regions can communicate in their preferred languages. That helps better understand the specific needs of various markets. This continuous communication and feedback mechanism has been instrumental in helping CoinEx adapt to the ever-changing market landscape. 2025 and Beyond: CoinEx’s Vision Looking ahead, CoinEx is committed to building on its 2024 breakthroughs. The CEO outlined several key initiatives planned for 2025: New Activities and Broader Use CasesWe will introduce a range of CET value-added products and services, giving holders more opportunities to experience diverse financial services. We also aim to explore CET’s applications in payments and cross-chain transfers, expanding its real-world utility.Enhanced and Optimized Existing BenefitsBuilding on the 2024 upgrades, CoinEx may further improve trading fee discounts for CET holders, covering spot trading, contracts, and other transaction types. Additionally, we plan to launch exclusive financial products for CET holders, such as fixed-income programs or collaborative mining activities.Decision-Making ParticipationCET holders may gain voting rights on major platform decisions, such as project listings and product development, allowing them to actively participate in the platform’s growth. They will also receive priority access to exclusive activities, airdrops, and time-limited offers.Community Incentive ProgramsCoinEx may introduce a reward mechanism based on CET holding duration to encourage long-term holders. CET holders may also be incentivized to promote the CoinEx platform and receive additional rewards.Global PromotionExpanding CET’s value proposition in more regions through localized marketing to attract a global user base. In addition, regularly publishing data on CET buybacks, burns, and allocations to build user trust. Personal Insights from the CEO CoinEx’s mission is making crypto trading easier, supported by a stable and comprehensive ecosystem designed to prioritize user needs. These crypto exchange provides a “good, fast, and comprehensive” selection of tokens. By carefully curating high-quality projects and simplifying trading processes, even beginners can easily navigate the platform. Simple and Intuitive Products: CoinEx offers a user-friendly interface (UI) and straightforward trading functions, enabling users to get started quickly.Educational Resources: In 2024, CoinEx launched CoinEx Insight, which delivers foundational knowledge about cryptocurrencies, market analysis, and trends. To date, over 2,500 original industry insights have been published, helping users stay updated on market dynamics while investing.Exclusive Rewards for Beginners: CoinEx regularly hosts new user registration reward campaigns, lowering the barriers to entry for the crypto market.AI Analysis and Copy Trading: Tools like AI-powered analysis and copy trading provide trading suggestions, helping beginners learn while making informed decisions. MEME Coins and Market Trends Discussing the strong performance of MEME coins in 2024, the CEO noted their appeal lies in community-driven culture and speculative opportunities. While their future depends on market conditions, CoinEx remains committed to providing timely access to promising MEME coins. Conclusion: A Message to Global Users "The crypto world knows no borders; opportunities are everywhere," the CEO said. He emphasized CoinEx's commitment to making cryptocurrency trading accessible, safe, and innovative for all customers globally. About CoinEx Established in 2017, CoinEx is a global cryptocurrency exchange committed to making trading easier. The platform provides a range of services,including spot and futures trading, margin trading, swap, automated market maker (AMM), and financial management services for over 10 million users across 200+ countries and regions.Since its establishment, CoinEx has steadfastly adhered to a "user-first" service principle. With the sincere intention of nurturing an equitable, respectful and secure crypto trading environment, CoinEx enables individuals with varying levels of experience to effortlessly access the world of cryptocurrency by offering easy-to-use products. To learn more about CoinEx, visit: Website | Twitter | App｜Telegram | LinkedIn | Facebook | Instagram | YouTube Contact:Karen Hupr@coinex.com Disclaimer: This content is provided by CoinEx. The statements, views and opinions expressed in this column are solely those of the content provider. The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Please conduct your own research and invest at your own risk. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d090cf81-f83c-47cf-bfa3-828049dec302
Ashland signs definitive agreement to sell Avoca business to Mane - ForexTV
Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions. Ashland's Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin. The Avoca business line represents the last entity from Ashland’s previous acquisition of Pharmachem. “The Avoca business is a strong player in the fragrance fixative space with a dedicated team and attractive manufacturing capabilities to meet customer needs,” said Guillermo Novo, chair and chief executive officer, Ashland. “I want to thank the Avoca employees for their dedication and commitment to Ashland and to our customers.” Squire Patton Boggs is acting as legal advisor to Ashland. Update Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” should,” “plans” and “intends” and the negative of these words or other comparable terminology. In addition, Ashland may from time to time make forward-looking statements in its annual report to shareholders, quarterly reports and other filings with the Securities and Exchange Commission (SEC), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance, financial condition, operating cash flow and liquidity, as well as the economy and other future events or circumstances. These statements include, but may not be limited to, statements about the sale of the Avoca business, including the expected timing for closing of the sale. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements, including any delay in the satisfaction of customary closing conditions for the sale of the Avoca business. Factors that will influence the impact on our business and operations include, without limitation, risks and uncertainties affecting Ashland that are described in its most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland’s website at http://investor.ashland.com or on the SEC’s website at http://www.sec.gov. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether because of new information, future events or otherwise. Information on Ashland’s website is not incorporated into or a part of this news release. About Ashland Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 3,200 passionate, tenacious solvers thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. About ManeFounded in 1871 by Victor Mane, MANE is one of the leading producers and suppliers of fragrances and flavours globally. Since inception, the company has been owned and managed by five successive generations of the Mane family. MANE is a global group, operating 29 production facilities worldwide and more than 79 sites in more than 40 countries and employing over 8,000 collaborators. The first French company and the fifth largest fragrances and flavours producer in the world and are recognised as the fastest growing major company within the industry. ™ Trademark, Ashland or its subsidiaries, registered in various countries. FOR FURTHER INFORMATION: Investor Relations Ashland:Media Relations Ashland:William C. WhitakerCarolmarie C. Brown+1 (614) 790-2095+1 (302) 995-3158wcwhitaker@ashland.comccbrown@ashland.com Mane Contacts: Eliane ColorettiBertrand Boulin+ 33 4 93 09 70 00+ 33 4 93 09 70 00Eliane.COLORETTI@MANE.comBertrand.BOULIN@mane.com Attachment Ashland_signs_definitive_ agreement_to_sell_Avoca_business_20241223
European Shares Seen Mixed In Light Trade Before Christmas Shutdown - ForexTV
European markets are poised for a varied opening on Tuesday, with trading activity expected to remain subdued as the Christmas holiday approaches. Today, regional exchanges will close early and will remain closed on Wednesday in observance of Christmas. Similarly, U.S. markets will also have shortened hours on Christmas Eve and will remain closed on Wednesday.Asian markets showed broad gains, driven by a rally in several leading global technology companies, such as Nvidia, Broadcom, Alphabet, and Meta, which supported U.S. benchmark indices in the overnight session.The U.S. dollar held firm under the support of rising bond yields, while oil and gold maintained modest gains in the Asian trading environment.U.S. stocks experienced an upward trend overnight, and Treasury yields reached nearly a seven-month peak following the release of mixed economic indicators. Data showed a decline in U.S. consumer confidence in December, contrasted by a rebound in new home sales and an increase in core capital goods orders in November.The Dow Jones Industrial Average gained 0.2 percent, marking its third consecutive day of gains, while the S&P 500 rose by 0.7 percent and the technology-focused Nasdaq Composite advanced by 1 percent.Monday saw European stocks presenting a mixed performance amidst concerns over tariff threats from the Trump administration and ongoing political instability in Germany and France. The pan-European STOXX 600 index edged up by 0.1 percent, with France's CAC 40 closing slightly down, Germany's DAX slipping by 0.2 percent, while the U.K.'s FTSE 100 saw a modest increase of 0.2 percent.The material has been provided by InstaForex Company - www.instaforex.com
Sensex, Nifty Give Up Early Gains - ForexTV
In early trading on Tuesday, Indian equities experienced volatility, despite receiving favorable signals from global markets. The S&P/BSE Sensex saw a decrease of 92 points, equating to a 0.1 percent drop to reach 78,447, thereby relinquishing initial gains. Similarly, the broad NSE Nifty index decreased by 32 points or 0.1 percent, landing at 23,721.Several major companies, including Bharti Airtel, SBI Life, Shriram Finance, Tata Steel, and JSW Steel, experienced declines of approximately 1 percent. In contrast, TCS and Tata Motors both posted gains of about 1 percent.Adani Enterprises maintained a steady position following its agreement to acquire an 85.8 percent stake in Air Works India (Engineering). Meanwhile, Kalyani Investment Company dropped by 1.3 percent after resolving a dispute with the capital market regulator, SEBI.Waaree Energies saw a slight increase after its board approved three investment initiatives totaling Rs 850 crore. Conversely, Symphony experienced a decline upon expanding its loan facility for its Australian subsidiary.Aurionpro Solutions saw an uptick of 2.7 percent with the announcement of its expansion into the European market through the acquisition of Fenixys. However, Vedanta faced a 2.6 percent fall as it went ex-dividend.The material has been provided by InstaForex Company - www.instaforex.com
Press release: Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis - ForexTV
Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis alfapump® is the first US approved active implantable medical device (Class III) for the treatment of recurrent or refractory ascites due to liver cirrhosisPMA Approval and FDA Breakthrough Device DesignationUS market opportunity estimated at over $2 billion in 2025, growing at 9%1 due to MASH/NASH2 and alcoholic liver diseaseUS commercial launch planned for H2 2025 through speciality salesforce targeting liver transplant centersPOSEIDON pivotal study shows virtual elimination of therapeutic paracentesis and improvement in quality of life3, 4Over 1,000 alfapump Systems implanted KOL webcast January 8th, 2025 at 15:00 CET / 09:00 am ESTGhent, Belgium – 23 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that it has received Premarket Approval (PMA) from the US Food and Drug Administration (FDA) to market alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis in the United States. With this major regulatory milestone, achieved earlier than market expectations, alfapump is the first active implantable medical device in the US that automatically and continuously removes ascites from the abdomen into the bladder. The Company estimates there will be approximately 70,000 patients in the US with recurrent or refractory ascites, representing a market opportunity in excess of $2 billion for the alfapump in 2025. This population is forecast to reach 130,000 patients by 2032, primarily driven by NASH/MASH and alcoholic liver disease1. Dr. H.E. Vargas, M.D., Professor of Medicine for the Mayo Clinic College of Medicine (Phoenix, Arizona, US), POSEIDON Study Principal Investigator, commented: “The approval of alfapump by the FDA opens the door to a breakthrough therapeutic option for patients with ascites. The introduction of the system will be welcome by patients, families and their care providers as this technology not only provides effective treatment, but also has been shown to improve quality of life4.” Ian Crosbie, Chief Executive Officer of Sequana Medical, continued: "With a standard of care that has seen minimal change in thousands of years, today marks a huge milestone for the large and growing liver ascites community in the US. Our vision is to transform the lives of these patients. Recurrent or refractory liver ascites is a devastating condition with a terrible impact on the lives of our patients and their caregivers, not only for the painful and burdensome paracentesis procedure itself but also in the weeks leading up to each drainage. The POSEIDON clinical study results demonstrate that the alfapump can virtually eliminate the need for therapeutic paracentesis, and improve patient quality of life, with a safety profile comparable to standard of care, delivering a twenty-first century solution that can allow these patients to take back their lives3,4. We wish to thank all the patients and investigators who made this possible by participating in the POSEIDON study. With over 1,000 alfapump systems implanted to date, we look forward to starting commercialisation in H2 2025, bringing this innovative solution to many more patients in need.” The Company is preparing for the US commercial launch of the alfapump System in H2 2025, through a focused specialty sales force concentrating on the 90 liver transplant centers that represent the large majority of target customers. The Company has received FDA Breakthrough Device Designation for the alfapump System and has applied, and expects to receive, NTAP (new technology add-on payments) which should facilitate patient access to the device. In addition to the existing ICD-10 procedure codes for the alfapump procedure, the American Medical Association has granted six new CPT®5 III reimbursement codes, available for use by healthcare professionals and payors since July 1st, 2024, for procedures related to the alfapump System. “We are highly encouraged by the enthusiastic feedback for the alfapump that we are receiving from the clinical community – there is a clear need for improved treatment options and we are putting in place the commercial team to deliver our novel therapy. Preparations for commercial launch are underway, and we are already working with target centers for the initial commercial launch planned for H2 2025. It is a huge privilege to bring such a breakthrough in therapy to the clinical and patient communities, and we are excited to work with them to establish alfapump as the new standard of care” commented Martijn Blom, Chief Commercial Officer of Sequana Medical. Timur Resch, Global Vice President QM/QA/RA at Sequana Medical, who has been leading the regulatory process since 2016, added: “The receipt of the PMA approval for our alfapump System is a major milestone for our company and reflects many years of diligent work by the Sequana team. We wish to thank the FDA for its collaboration and support in bringing this highly important breakthrough device to US patients who will be very grateful for this new treatment option.” KOL Webcast on January 8, 2025 – 3pm CET, 9am ETThe Company will be hosting a further webcast with key opinion leaders on January 8, 2025 at 3pm CET, 9am ET to discuss the US FDA approval of alfapump, the clinical need and the planned commercial US roll-out. Registration webcast: please click hereRegistration conference call (only if you wish to participate in the Q&A): please click here. Once registered, you will receive dial-in numbers and a confirmation code. The webcast and conference call will be conducted in English and a replay will be available on Sequana Medical’s website shortly after. For more information, please contact:Sequana Medical Investor relationsE: IR@sequanamedical.com T: +44 (0) 797 342 9917 Optimum Strategic CommunicationsNick Bastin, Vici Rabbetts, Elena BatesE: Sequana@optimumcomms.comT: +44 (0) 208 078 4357 About alfapump in recurrent or refractory ascites due to liver cirrhosis & the POSEIDON studyRecurrent or refractory ascites is a severe condition characterized by the accumulation of fluid in the abdomen. The current standard treatment involves therapeutic paracentesis, an invasive and burdensome procedure that drains ascites from the abdomen using a large needle over an extended period. The alfapump is approved by the US FDA for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical device in the US that automatically and continuously removes ascites from the abdomen into the bladder, where it is naturally eliminated through urination. To date, over 1,000 alfapump systems have been implanted. The US market of recurrent and refractory ascites due to liver cirrhosis is forecast to grow by an average of 9% per year, from approximately 70,000 patients in 2025 to 130,000 patients by 2032, primarily driven by the increasing prevalence of NASH / MASH6. The total market opportunity for alfapump is estimated at over $2 billion in 2025, including approximately $500 million from the Company’s initial priority target market of patients requiring at least 12 paracenteses per year. The FDA’s approval of the PMA is based on the successful execution of Sequana Medical’s pivotal POSEIDON study, a landmark study across 18 centers in the US and Canada with a total of 69 patients implanted with the alfapump. The primary effectiveness endpoints at six months post-implantation in the Pivotal Cohort7 exceeded the predefined thresholds with statistical significance, and primary safety endpoint data was in line with expectations8. Data at 12 months post-implantation continued to show a strong and durable clinical profile, virtually eliminating the need for therapeutic paracentesis and delivering an improvement in quality of life (as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q))9. At AASLD’s The Liver Meeting in November 2024, key POSEIDON investigators reported that the alfapump virtually eliminated the need for large volume paracentesis at 24 months, with overall survival of 62%10. Data from the patient preference study and a matched cohort analysis of the NACSELD-III registry with the POSEIDON Pivotal Cohort indicated that US patients have a strong preference for the alfapump vs standard paracentesis procedures and that the safety profile of the alfapump is comparable to standard of care.11 About Sequana Medical Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, intolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing "diuretic resistant" patient population. alfapump® and DSR® are Sequana Medical's proprietary platforms that work with the body to treat diuretic-resistant fluid overload, and are intended to deliver major clinical and quality of life benefits for patients, while reducing costs for healthcare systems. The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Device Designation in 2019. Results of the Company's RED DESERT and SAHARA proof-of-concept studies in heart failure published in European Journal of Heart Failure in April 2024 support DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements12. The independent Data Safety Monitoring Board approved the start of the randomized MOJAVE cohort of up to a further 30 patients, which is planned after alfapump US PMA approval. Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com. Indication for Use: The alfapump® System is intended for single patient use only in adult patients with refractory or recurrent ascites due to liver cirrhosis. It is indicated for the removal of excess peritoneal fluid from the peritoneal cavity into the bladder, where it can be eliminated through normal urination. Contraindications: The alfapump® System is MRI unsafe. Hyperbaric oxygen therapy is contraindicated. Warnings, Risks, and Precautions: Consider risks associated with implanting the alfapump® System including risk of peritoneal cavity infections, Coagulopathy, Small bladder capacity and/or obstructive uropathy. The following procedures or therapies could impact the alfapump® System function: Supersonic therapy and high-frequency heat therapy, Transcutaneous Electrical Nerve Stimulation (TENS), Lithotripsy, Defibrillation, Radiation therapy, Electrocautery, or use of other implantable medical devices and wearable devices. Adverse Events: In addition to procedure related risks the following Adverse Events may occur: pump pocket hematoma, skin erosion, infection, pump migration, catheter clogging or other catheter complications resulting in tissue damage or loss of or change in therapy, genito-urinary complications, reduced kidney function, hepatic encephalopathy, progression of liver disease, and other systemic effects. P230044 PMA approval letter on file U.S. Federal law restricts alfapump System to sale by or on the order of a physician. The alfapump® System is currently not approved in Canada. DSR® therapy is still in development and is currently not approved in any country. The safety and effectiveness of DSR® therapy has not been established. Note: alfapump® and DSR® are registered trademarks. Forward-looking statements This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release. 1 Based on US and Canada market assessment conducted by highly experienced international consulting group2 NASH – Non-alcoholic steatohepatitis; MASH – Metabolic dysfunction-associated steatohepatitis3 POSEIDON study results in SSED (PMA P230044, FDA approval letter on file) – 100% median reduction in number of therapeutic paracentesis per month in Pivotal Cohort4 Quality of life as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q)5CPT copyright 2024 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.6 Based on US and Canada market assessment conducted by highly experienced international consulting group7 The Pivotal Cohort is used for the primary effectiveness endpoints and consists of 40 patients implanted with the alfapump8 Data reported in press release of 25 October 20229 Data reported in press release of 19 October 202310 Based upon the pivotal cohort of the POSEIDON study, data reported in press release of 18 November 202411 Data reported in press release of 19 October 2023; Patient Preference study conducted by RTI Health Solutions, and matched cohort analysis presented by Dr. Bajaj at EASL Congress 2024.12 Data reported in press release of 25 March 2024; mean increase of 326% in six-hour urinary sodium excretion at 3 months follow up vs baseline, and 95% reduction of loop diuretics over same period Attachments 241223 Press release_PMA approval alfapump_ENG_FINAL 241223 Press release_PMA approval alfapump_NL_FINAL
Financing facility update - ForexTV
23 December 2024 ICG Enterprise Trust announces increased credit facility ICG Enterprise Trust plc (‘ICGT’) has increased the size of its revolving credit facility (‘RCF’) from €240m to €300m to accommodate portfolio growth. This change was effective from 20 December 2024. There are no other changes to the terms previously disclosed on 1 June 2023 and 5 June 2024. At 13 December 2024, ICGT had total available liquidity of £84m (31 July 2024: £126m). This comprised £8m cash and £76m (€92m) undrawn RCF. Pro forma for the increase announced today, ICGT would have had total available liquidity of £134m. Enquiries Analyst / Investor enquiries Chris Hunt, Head of Corporate Development and Shareholder Relations+44 (0) 20 3545 2000 Media Clare Glynn, Corporate Communications, ICG +44 (0) 20 3545 1395 Website www.icg-enterprise.co.uk About ICG Enterprise Trust ICG Enterprise Trust is a leading listed private equity investor focused on creating long-term growth by delivering consistently strong returns through selectively investing in profitable, cash-generative private companies, primarily in Europe and the US, while offering the added benefit to shareholders of daily liquidity. We invest in companies directly as well as through funds managed by Intermediate Capital Group plc ('ICG') and other leading private equity managers who focus on creating long-term value and building sustainable growth through active management and strategic change. Disclaimer The information contained herein does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for, any securities in any jurisdiction where such an offer or solicitation is unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on ICG Enterprise Trust PLC (the "Company") or its affiliates or agents. Equity securities in the Company have not been and will not be registered under the applicable securities laws of the United States, Australia, Canada, Japan or South Africa (each an “Excluded Jurisdiction”). The equity securities in the Company referred to herein and on the pages that follow may not be offered or sold within an Excluded Jurisdiction, or to any U.S. person ("U.S. Person") as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or to any national, resident or citizen of an Excluded Jurisdiction. The information on the pages herein may contain forward looking statements. Any statement other than a statement of historical fact is a forward looking statement. Actual results may differ materially from those expressed or implied by any forward looking statement. The Company does not undertake any obligation to update or revise any forward looking statements. You should not place undue reliance on any forward looking statement, which speaks only as of the date of its issuance.
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - ForexTV
Addition is part of the annual reconstitution of the Nasdaq Biotech Index (NBI)Inclusion criteria include minimum market capitalization and daily trading volumes Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its stock will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI). The addition comes as a part of the annual reconstitution of the index. Alvotech’s inclusion in the NBI will be effective when the U.S. market opens on Monday, December 23, 2024. The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet various eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. Nasdaq selects new constituents of the NBI once annually, in December. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube. Alvotech Forward Looking StatementsCertain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, and market launches. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “aim” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to maintain criteria for inclusion in stock market indexes; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech’s estimates of expenses and profitability; (6) Alvotech’s ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (10) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (11) the ability of Alvotech’s partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (12) Alvotech’s ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (13) the success of Alvotech’s current and future collaborations, joint ventures, partnerships or licensing arrangements; (14) Alvotech’s ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (15) Alvotech’s ability to manufacture sufficient commercial supply of its approved products; (16) the outcome of ongoing and future litigation regarding Alvotech’s products and product candidates; (17) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company’s business, financial position, strategy and anticipated milestones; and (18) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson, VPalvotech.ir@alvotech.com
MIDNIGHT HUB DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Midnight Hub Investors to Secure Counsel Before Important Deadline in Securities Class Action - ForexTV
NEW YORK, Dec. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ROOMS non-fungible tokens (“NFTs”) and Digital Nomads NFTs issued by Midnight Hub between January 15, 2023 and March 31, 2024, both dates inclusive (the “Class Period”), of the important January 6, 2025 lead plaintiff deadline. SO WHAT: If you purchased ROOMS NFTs and Digital Nomads NFTs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Midnight Hub class action, go to https://rosenlegal.com/submit-form/?case_id=30701 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 6, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants’ statements promoting the NFTs were untrue or misleading statements of material fact. In truth, at the time defendants sold the NFTs, defendants had no plan for developing Midnight Hub’s infrastructure or any of the platform’s decentralized projects such as the Digital Nomads TV. In fact, defendants had no plans for the future of Midnight Hub aside from profiting off the hype and excitement around the project. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Midnight Hub class action, go to https://rosenlegal.com/submit-form/?case_id=30701 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com
Falcon Oil & Gas Ltd. - Change of Auditors - ForexTV
FALCON OIL & GAS LTD. (“Falcon”) Change of Auditors 23 December 2024 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) announces that BDO Canada LLP has been appointed as Falcon’s new auditor, replacing BDO LLP in the UK. Ends. CONTACT DETAILS: Falcon Oil & Gas Ltd. +353 1 676 8702Philip O'Quigley, CEO+353 87 814 7042Anne Flynn, CFO+353 1 676 9162 Cavendish Capital Markets Limited (NOMAD & Broker)Neil McDonald / Adam Rae+44 131 220 9771 About Falcon Oil & Gas Ltd. Falcon Oil & Gas Ltd is an international oil & gas company engaged in the exploration and development of unconventional oil and gas assets, with the current portfolio focused in Australia. Falcon Oil & Gas Ltd is incorporated in British Columbia, Canada and headquartered in Dublin, Ireland. For further information on Falcon Oil & Gas Ltd. please visit www.falconoilandgas.com Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Falcon assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to Falcon. Additional information identifying risks and uncertainties is contained in Falcon’s filings with the Canadian securities regulators, which filings are available at www.sedarplus.ca Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics - ForexTV
Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an additional USD 7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The new funding supports the progression of Basilea’s novel antibiotic candidate BAL2420 (LptA inhibitor) towards the start of first-in-human clinical studies, which is expected mid-2026. Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: "We are very pleased by CARB-X’s continued support for the development of this promising first-in-class drug candidate. LptA inhibitors have the potential to address an unmet medical need in the hospital-based treatment of severe infections, caused by Gram-negative bacteria. We look forward to working with CARB-X to bring BAL2420 to patients." BAL2420 belongs to one of the very few novel classes of antibiotics in development. It is targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy.1 Enterobacteriaceae have been highlighted by the World Health Organization (WHO) as priority pathogens, against which new antibiotics are urgently needed.2 Basilea has acquired the LptA antibiotics program from Spexis AG in early 2024. In April this year, Basilea announced that it was awarded an initial CARB-X grant of up to USD 0.9 million to support early preclinical activities. The successful completion of these activities resulted in the nomination of BAL2420 as a drug candidate and also led to a final milestone payment from Basilea to Spexis. CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About CARB-X CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. CARB-X supports innovative therapeutics, preventatives and rapid diagnostics. CARB-X is led by Boston University and funded by a consortium of governments and foundations. CARB-X funds only projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. https://carb-x.org/ | X (formerly Twitter) @CARB_X About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhDHead of Corporate Communications & Investor RelationsBasilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b4123 AllschwilSwitzerlandPhone+41 61 606 1102E-mailmedia_relations@basilea.cominvestor_relations@basilea.com This ad hoc announcement release can be downloaded from www.basilea.com. References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed: December 22, 2024) Attachment Press release (PDF)
Harmonisation of the articles of the group's Estonian subsidiaries - ForexTV
Liven AS has harmonised the articles of associations of the group's subsidiaries registered in Estonia and supplemented them, where necessary, with the right to establish a voluntary reserve. Among others, the amendment concerns the following subsidiaries that are considered significant subsidiaries according to the requirements of Nasdaq Tallinn:Liven Kodu OÜLiven Kodu 6 OÜLiven Kodu 12 OÜLiven Kodu 14 OÜLiven Kodu 15 OÜLiven Kodu 16 OÜLiven Kodu 18 OÜLiven Kodu 20 OÜ Translation of the item added to the articles of association (original in Estonian): One or more voluntary reserves (hereinafter referred to as the Voluntary Reserve) may be established by decision of the shareholders of the limited liability company (the Company), which shall be constituted either from annual allocations of net profits or from additional financial contributions or other contributions to the Company's equity. Contributions to the Voluntary Reserve may be made in cash or in other assets (including, for example, by way of offsetting a shareholder's claim). The value of the contribution in kind is determined by the management of the Company. The amount of the Voluntary Reserve is determined by a decision of the shareholders, which also determines the amount of the contributions to be paid by the shareholders and the procedure for their payment (the contributions to the Voluntary Reserve being distributed in proportion to the shareholdings of the shareholders in the Company). Once the formation of the Voluntary Reserve from the contributions of the shareholders has been decided, each shareholder will be obliged to make a contribution corresponding to the amount set out in the shareholders' decision (regardless of whether the shareholder participated in the adoption of the decision or opposed it). Voluntary Reserves, if established, shall be deemed to form part of the Company's equity capital (including contributions to the Reserve being deemed to be a contribution to equity capital) and may be used to cover losses, to increase share capital or to make distributions to shareholders, as determined by a resolution of the shareholders (or, in the case of a resolution of the shareholders, by the management of the Company). Any payments to shareholders from the Voluntary Reserves shall be distributed among the shareholders in proportion to the amount of their contributions to the Voluntary Reserve. Payments may be made only to the extent of the contributions made to the Voluntary Reserve, but no more than the amount that does not result in a reduction of the net assets below the minimum net assets requirement set out in § 176 of the Commercial Code. No interest or other charge shall be calculated on contributions to the Voluntary Reserve. Voluntary Reserves shall be deemed to be "other reserves" within the meaning of § 155(1)(1) and § 1992(2) of the Commercial Code. After registration of the amendments by the Tartu District Court Registration Department, the articles of association will be available in the e-business register https://ariregister.rik.ee/eng. Joonas JoostLiven AS CFOE-mail: joonas.joost@liven.ee
Fagron updates on FDA communication regarding the June 2024 inspection at Wichita - ForexTV
Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Following the FDA’s routine inspection at Fagron’s Wichita facility conducted in June 2024, the Company received a warning letter from the FDA (Warning Letter) on December 19, 2024. The Warning Letter requires Fagron to enhance processes for investigating discrepancies, and validations of future manufacturing capacity. The majority of these improvements have already been addressed, and Fagron is collaborating with the FDA to clarify any outstanding items and achieve a satisfactory resolution. After the June inspection, the Company responded to the FDA on July 19, August 30, September 27, October 25, and November 22, 2024 addressing the Agency’s observations. Additionally, on August 15, 2024, out of an abundance of caution, the Company initiated a voluntary, class 2, batch-specific recall in good faith with the Agency. Fagron has not received any adverse events related to this recall, and there has been no material impact on the business. Fagron’s top priority is providing safe and effective sterile drug products to our customers and their patients. We are very confident in our robust systems and the quality and safety of the products we produce. Against the backdrop of elevated regulatory requirements, we remain close to our customers and partners to collectively enhance quality standards across the industry. Management will host a conference call for investors and analysts to address any questions on December 23, 2024 at 09:30am CET. Dial in details are as follows: Dial in numbers USA Local: +1 786 697 3501 USA Toll Free: 866 580 3963 Brussels: +32 (0) 2 789 8603 Belgium Toll Free: 0800 746 68 Berlin: +49 (0) 30 3001 90612 Amsterdam: +31 (0) 20 708 5073 Netherlands Toll Free: 0 800 022 9132 UK Toll Free: 0808 109 0700 Further informationKarin de JongChief Financial Officerinvestors@fagron.com About FagronFagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in more than 30 countries around the world. Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam. Important information regarding forward-looking statements Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason. In the event of differences between the English translation and the Dutch original of this press release, the latter prevails. Attachment Fagron updates on FDA communication regarding the June 2024 inspection at Wichita
KSPI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Joint Stock Company Kaspi.kz Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ForexTV
NEW YORK, Dec. 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Joint Stock Company Kaspi.kz (“Kaspi.kz” or “the Company”) (NASDAQ: KSPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kaspi.kz securities between January 19, 2024 and September 19, 2024, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/KSPI. Case Details The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Kaspi.kz continued doing business with Russian entities, and also providing services to Russian citizens, after Russia’s 2022 invasion of Ukraine, thereby exposing the Company to the undisclosed risk of sanctions; (2) the Company engaged in undisclosed related party transactions; (3) certain of the Company’s executives have links to reputed criminals; and (4) as a result, defendants’ statements about Kaspi.kz’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What's Next? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/KSPI. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Kaspi.kz you have until February 18, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. There is No Cost to You We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful. Why Bronstein, Gewirtz & Grossman Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. Follow us for updates on LinkedIn, X, Facebook, or Instagram. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Nathan Miller 332-239-2660 | info@bgandg.com